Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

EW Edwards Lifesciences SEC Filings & Insider Trading Activity 2026

company
CIK 1099800116 filings
S&P 500

EW at a glance

Edwards Lifesciences (EW, SEC CIK 1099800) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Edwards Lifesciences (EW) reported revenue of $6.1 billion (up 11.5% from FY2024) and net income of $1.1 billion. Diluted EPS was $1.83.
  • As of September 30, 2026, 44 institutional investment managers tracked by SignalX reported holding Edwards Lifesciences (EW) shares worth $20.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Lippis Daniel J. on November 10, 2026 of 619 shares at $104.25 per share.
  • In the last 90 days, EW insiders reported 0 open-market purchases ($0) and 11 open-market sales ($10.9M) on Form 4, a net sale of $10.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$6.1B
+11.5% vs prior year
Insiders · 90 days
0 buys · 11 sells
Net −$10.9M
13F holders
44 funds
$20.8B · +0 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 1.01 · Item 2.03

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue $6.07B, up $628.1M (+11.5% YoY); TMTT best-performing segment +56.4% to $550.6M; Surgical weakest at +4.9% to $1.03B
  • Gross profit as % of net sales decreased due to higher operational expenses; litigation expenses surged to $325.4M in 2025 vs $40.4M in 2024; effective tax rate 17.0% vs 9.8%
  • Operating cash flow $1.60B, up $1.05B YoY; capex $260.2M in 2025, guided ~$280M in 2026
  • Share buybacks $884.7M (11.7M shares) in 2025; $2.0B repurchase authority remaining; no dividends mentioned; $600M senior notes due 2028 outstanding
  • Key risks: IRS transfer pricing dispute ($269.3M additional tax claimed), Pillar Two added $19.1M tax expense, and ongoing IP litigation

Business Overview

  • Structural heart pure-play: TAVR, TMTT, and Surgical segments targeting aortic, mitral, tricuspid, and pulmonic valve disease
  • TMTT fastest-growing segment: revenue share expanded to 9% in FY2025 vs 7% in FY2024 and 4% in FY2023
  • KONECT RESILIA aortic valved conduit launched in Europe in 2025; EARLY TAVR trial 2024 data supporting asymptomatic aortic stenosis indication expansion
  • R&D spend ~18% of 2025 sales, up ~2% YoY; ~16,000 employees worldwide as of December 31, 2025
  • TAVR share of net sales declined to 74% in FY2025 from 77% in FY2023, reflecting deliberate portfolio diversification toward TMTT

Risk Factors

  • Section 232 investigation by U.S. Dept. of Commerce into medical device imports could impose tariffs, raising manufacturing costs and disrupting Edwards' supply chain
  • EU MDR compliance risk: unresolved EU-Switzerland Mutual Recognition Agreement may block Edwards from placing devices on EU market via Swiss operations
  • Single-source supplier dependency for key materials; regulatory burden of FDA qualification makes replacement difficult and costly
  • Competitors introducing new TAVR/TMTT technologies competing for same hospital catheterization labs, directly constraining Edwards' procedure volumes
  • GDPR, HIPAA, and CCPA compliance exposure across multiple jurisdictions; GDPR noncompliance penalties and CCPA private right of action create layered financial liability

AI summary of the EW 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors reported since the December 31, 2025 Form 10-K
  • Carried-forward risks remain governed by the 2025 Annual Report’s Risk Factors section

Management Discussion & Analysis

  • Quarterly revenue $1,715.5M, up 10.5% YoY from $1,553.1M
  • TMTT best-performing segment: $209.5M, up 44.3% YoY; Surgical lowest growth at 2.5%
  • Effective tax rate 17.0% vs 16.1% YoY; impairment charges $220.2M
  • Operating cash flow $1,266.0M, up $121.7M; share repurchases $714.0M
  • Tariffs pose potential demand and cost headwinds; 2026 Pillar Two tax expense expected at approximately $45.0M

AI summary of the EW 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Edwards entered an amended and restated five-year credit agreement on November 19, 2026
  • Facility refresh replaces the July 15, 2022 credit agreement

Item 2.03: Creation of a Direct Financial Obligation

  • New five-year $750 million multi-currency unsecured revolving facility replaces 2022 credit agreement
  • Maturity extended to November 19, 2031, supporting liquidity and general corporate purposes
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Edwards issued third-quarter 2026 financial results on November 4, 2026
  • Investor-relevant figures and management commentary are contained in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q3 sales $1.72B, up 10.5%, with adjusted EPS $0.80, up 19% year over year
  • TAVR sales $1.24B, up 8.0%, supporting continued leadership in Edwards’ core structural-heart franchise
Filed Aug 28, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Donald E. Bobo Jr. plans to retire by mid-2027 from Corporate Vice President, Strategy and Corporate Development
  • Successor search begins promptly, with duties expected to transition during 2027

AI summaries of EW 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EW

Don't miss the next EW filing

  • Alerts as it files. A push when EW files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EW, by share count.
  • Ask anything. An AI agent that reads every EW filing and answers with sources.

EW alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Dahl Andrew M.FNov 13, 2026$105.80
Lippis Daniel J.MNov 10, 2026-
Lippis Daniel J.SellNov 10, 2026$104.25
Lippis Daniel J.MNov 10, 2026$72.68
Zovighian Bernard JMNov 9, 2026-
Zovighian Bernard JSellNov 9, 2026$102.78
BOBO DONALD E JRSellNov 9, 2026$103.05
Zovighian Bernard JMNov 9, 2026$72.68

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$5.4B$6.1B
Gross Profit-$4.3B$4.7B
Operating Income-$1.4B$1.3B
Net Income-$4.2B$1.1B
Gross Margin-79.5%78.0%
Op. Margin-25.3%20.8%
Net Margin-76.7%17.7%
Balance Sheet
Total Assets$9.4B$13.1B$13.7B
Equity-$10.0B$10.3B
ROE-41.8%10.4%
Per Share
EPS-$6.97$1.83
Cash Flow
Operating CF-$542.3M$1.6B
CapEx$253.0M$252.4M$260.2M

Source: XBRL data in Edwards Lifesciences (EW)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EW share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EW shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202644$20.76B
Q2 202644$22.46B
Q1 202645$19.63B
Q4 202540$21.76B
Q3 202542$21.72B
Q2 202542$20.03B
Q1 202543$13.87B
Q4 202438$11.37B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 338 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EW filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
4Nov 13, 2026--
4Nov 10, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 8, 2026--
4Sep 14, 2026--
4Sep 14, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Aug 31, 2026--
8-KAug 28, 2026Analysis-
4Aug 28, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 11, 2026--
10-QAug 4, 2026Analysis
4Jul 30, 2026--
4Jul 28, 2026--
4Jul 27, 2026--
8-KJul 23, 2026Analysis-
4Jul 13, 2026--
4Jul 10, 2026--

Related Health Care companies

All Health Care →

EW SEC filings: frequently asked questions

Are EW insiders buying or selling?

In the last 90 days, Edwards Lifesciences (EW) officers, directors and 10% owners reported no open-market purchases and 11 open-market sales worth $10.9 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold EW stock?

As of September 30, 2026, the largest Edwards Lifesciences (EW) holders among the 13F filers tracked by SignalX were BlackRock ($5.1 billion), Vanguard Capital Management LLC ($3.3 billion), State Street Corp ($2.3 billion), Vanguard Portfolio Management LLC ($2.3 billion), JPMorgan Chase & Co ($2.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was EW's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Edwards Lifesciences (EW) reported revenue of $6.1 billion (up 11.5% from FY2024) and net income of $1.1 billion. Diluted EPS was $1.83. The figures come from the XBRL data in the 10-K.

What are the main risks in EW's latest 10-K?

In the 10-K filed February 25, 2026, Edwards Lifesciences (EW) flagged: Section 232 investigation by U.S. Dept. of Commerce into medical device imports could impose tariffs, raising manufacturing costs and disrupting Edwards' supply chain. EU MDR compliance risk: unresolved EU-Switzerland Mutual Recognition Agreement may block Edwards from placing devices on EU market via Swiss operations. (AI summary of the Risk Factors section.)

What did EW report in its latest 8-K?

Edwards Lifesciences (EW) filed an 8-K on November 19, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). Edwards entered an amended and restated five-year credit agreement on November 19, 2026.

What are the latest EW SEC filings?

Edwards Lifesciences (EW) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 13, 2026.

What is EW's SEC CIK number?

Edwards Lifesciences (EW)'s SEC Central Index Key (CIK) is 1099800. EDGAR lists every EW filing under that number.

Ask anything about EW

The research agent reads EW's filings, financials, insider trades and 13F holders, then answers with sources.